Approximately 72% of global liver cancer cases occur in Asia
with China alone accounting for nearly half.
This disease steals lives and shatters families.
mRNA-based therapeutics are modular,
digital, and personalizable.
Their protein production is rapid, efficient,
avoiding the risk of genomic integration.
We engineered a modular mRNA system that programs cells to turn down a cancer protein TGF-β and turn up a tumor suppressor HNF4α.
We have engineered our LNP delivery vehicles by displaying GPC3 antibodies on their surface, which significantly improves their targeting of liver cancer cells.
